MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
MEIP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 1.71%30.2614.1%$178.05m
AMRNAmarin Corp. Plc -0.75%19.911.7%$164.99m
AXSMAxsome Therapeutics, Inc. -2.31%90.341.9%$138.85m
SAVACassava Sciences, Inc. -4.40%8.250.0%$90.26m
ARQLArQule, Inc. 0.15%20.000.6%$80.30m
BHCBausch Health Cos., Inc. 1.71%30.260.0%$72.67m
SAGESAGE Therapeutics, Inc. 3.12%76.408.6%$71.43m
JAZZJazz Pharmaceuticals Plc -0.36%151.052.3%$68.74m
GWPHGW Pharmaceuticals Plc -0.13%118.976.2%$67.44m
ICPTIntercept Pharmaceuticals, Inc. -3.76%106.1116.9%$60.73m
PRGOPerrigo Co. Plc -0.82%59.026.8%$58.59m
HZNPHorizon Therapeutics Plc 0.29%38.406.6%$58.11m
ICLRICON plc 0.38%175.784.2%$42.92m
ENDPEndo International Plc -2.27%6.048.8%$42.08m
CTLTCatalent, Inc. -1.03%60.842.4%$38.13m

Company Profile

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.